<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2611</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-757</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group></article-categories><title-group><article-title>Липидный спектр и функция почек до и после трансплантации печени</article-title><trans-title-group xml:lang="en"><trans-title>Lipid spectrum and function of kidneys before and after liver transplantation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Космачева</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosmacheva</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>350063, Краснодар, ул. Седина, д. 4;</p><p>350086, Краснодар, ул. 1 Мая, д. 167</p></bio><bio xml:lang="en"><p>Sedina st. 4, Krasnodar, 350063;</p><p>1 May st. 167, Krasnodar, 350086</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабич</surname><given-names>А. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Babich</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>350063, Краснодар, ул. Седина, д. 4;</p><p>350086, Краснодар, ул. 1 Мая, д. 167</p></bio><bio xml:lang="en"><p>Sedina st. 4, Krasnodar, 350063;</p><p>1 May st. 167, Krasnodar, 350086</p></bio><email xlink:type="simple">anna-babich1@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «КубГМУ» МЗ РФ;&#13;
ГБУЗ «НИИ‑ККБ № 1 им. проф. С. В. Очаповского» МЗ Краснодарского края</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University;&#13;
State Budgetary Healthcare Institution “Research Institute – Regional Clinical Hospital №1 n.a. professor S. V. Ochapovskiy” of Ministry of Health of Krasnodar Region</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>24</day><month>07</month><year>2019</year></pub-date><volume>59</volume><issue>6S</issue><fpage>17</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/757">https://cardio.elpub.ru/jour/article/view/757</self-uri><abstract><p>Актуальность. У пациентов после трансплантации печени смерть от сердечно‑сосудистых осложнений занимает третье место после отторжения донорского органа и инфекций. Важнейшими факторами развития сердечно‑сосудистых заболеваний являются дислипидемия и нарушение функции почек. Цель. Изучение липидного спектра и функции почек у реципиентов печени в реальной клинической практике и соответствия их коррекции актуальным клиническим рекомендациям по диагностике и лечению дислипидемий и хронической болезни почек (ХБП). Материалы и методы. Проведен ретроспективный анализ липидного спектра и функции почек у пациентов, оперированных в ГБУЗ «НИИ‑ККБ № 1 им. проф. С. В. Очаповского» г. Краснодара. Анализируются липидограмма, уровень креатинина и скорость клубочковой фильтрации (СКФ) у пациентов до трансплантации печени, а также спустя три года после операции. СКФ рассчитывали с использованием формулы CKD‑EPI (Chronic Kidney Disease Epidemiology Collaboration). Результаты. У реципиентов печени имеет место более высокое значение общего ХС по сравнению с исходным до операции – на 31% (p&lt;0,01). Уровень ХС до трансплантации был повышен у 13,7% (p&lt;0,01) пациентов, ТГ – у 12,3% (p&lt;0,01). Через 3 года после трансплантации повышение уровня ХС зарегистрировано у 42,6% (p&lt;0,01) и ТГ – у 37,9% больных (p&lt;0,01). Через 3 года наблюдалось снижение СКФ в сравнении с исходным значением на 22,6% (р&lt;0,001). Верификация ХБП и назначение статинов у пациентов проводились в единичных случаях. Уровни общего ХС и ТГ через 3 года после трансплантации печени имели обратную корреляционную связь со СКФ (r=–0,42; р&lt;0,01 и r=–0,36; р&lt;0,05). Заключение. В отдаленном послеоперационном периоде у реципиентов печени ухудшается липидный обмен и снижается СКФ. Дислипидемия тесно связана с прогрессированием нарушения функции почек у реципиентов печени, установлена обратная корреляция между СКФ и повышением уровня ХС и ТГ. Необходимо повысить внимание врачей к своевременной коррекции нарушения липидного обмена и выявления начальных проявлений почечной дисфункции.</p></abstract><trans-abstract xml:lang="en"><p>Background. In patients after liver transplantation cardiovascular complications is the third main reason of death afer allograf failure and infections. The most important factors in the development of cardiovascular diseases are dyslipidemia and impaired renal function. The aim of the study was to investigate the lipid spectrum and renal function in liver recipients in real clinical practice and the correspondence of their correction to current clinical recommendations for the diagnosis and treatment of dyslipidemia and chronic kidney disease (CKD). Methods. A retrospective analysis of lipid spectrum and renal function in patients who underwent OLT in Research Institute – Regional Clinical Hospital №1, Krasnodar was performed. The level of creatinine, GFR and lipid spectrum was studied before and 36 months after liver transplantation. The GFR was calculated using the formula CKD‑EPI (Chronic Kidney Disease Epidemiology Collaboration). Statistical analysis of the study results was made using the program Statistica 10. Results. Liver recipients have a significantly higher total cholesterol by 31.0% (p&lt;0.01) in comparison with the baseline before surgery. Total cholesterol was increased in 13.7% (p&lt;0.01), triglycerides in 12.3% (p&lt;0.01) before transplantation. Tree years after transplantation, the increasion in cholesterol was registered in 42.6% (p&lt;0.01) and triglycerides in 37.9% (p &lt;0.01), respectively. 3 years after transplantation reduction of GFR was observed in comparison with the baseline by 22.6% (p=0.00006). Verification of chronic kidney disease and statin administration in patients were carried out in some cases. The levels of total cholesterol and triglycerides had a reliable inverse correlation with GFR (r = ‑0.42; p&lt;0.01 and r = ‑0.36; p&lt;0.05). Conclusions. In the long‑term postoperative period there was an impaired lipid metabolism and decreased level of GFR. Dyslipidemia was closely related to the progression of renal dysfunction in liver recipients, an inverse correlation was established between the glomerular filtration rate and the increasion in cholesterol and triglyceride levels. It is necessary to increase the attention of physicians with regard to timely correction of lipid metabolism disorders and detection of initial manifestations of renal dysfunction.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>трансплантация печени</kwd><kwd>дислипидемия</kwd><kwd>статины</kwd><kwd>скорость клубочковой фильтрации</kwd><kwd>креатинин</kwd><kwd>хроническая болезнь почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver transplantation</kwd><kwd>dyslipidemia</kwd><kwd>statins</kwd><kwd>glomerular filtration rate</kwd><kwd>creatinine</kwd><kwd>chronic kidney disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wat KDS, Pedersen R, Kremers WK, Heimbach JK, Charlton MR. Evolution of Causes and Risk Factors for Mortality Post-Liver Transplant: Results of the NIDDK Long-Term Follow-Up Study: Long-Term Mortality Post-Liver Transplant. American Journal of Transplantation. 2010;10(6):1420–7. DOI: 10.1111/j.1600-6143.2010.03126.x</mixed-citation><mixed-citation xml:lang="en">Wat KDS, Pedersen R, Kremers WK, Heimbach JK, Charlton MR. Evolution of Causes and Risk Factors for Mortality Post-Liver Transplant: Results of the NIDDK Long-Term Follow-Up Study: Long-Term Mortality Post-Liver Transplant. American Journal of Transplantation. 2010;10(6):1420–7. DOI: 10.1111/j.1600-6143.2010.03126.x</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver International. 2009;30(7):948–57. DOI: 10.1111/j.1478-3231.2010.02274.x</mixed-citation><mixed-citation xml:lang="en">Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver International. 2009;30(7):948–57. DOI: 10.1111/j.1478-3231.2010.02274.x</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ciccarelli O, Kaczmarek B, Roggen F, DeReyck C, Goﬀete P, Danse E et al. Long-term medical complications and quality of life in adult recipients surviving 10 years or more afer liver transplantation. Acta Gastro-Enterologica Belgica. 2005; 68(3):323–30. PMID: 16268419</mixed-citation><mixed-citation xml:lang="en">Ciccarelli O, Kaczmarek B, Roggen F, DeReyck C, Goﬀete P, Danse E et al. Long-term medical complications and quality of life in adult recipients surviving 10 years or more afer liver transplantation. Acta Gastro-Enterologica Belgica. 2005; 68(3):323–30. PMID: 16268419</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Moiseev V. S., Mukhin N.A., Smirnov A.V., Kobalava Zh.D., Bobkova I.N., Villevalde S.V. et al. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology. 2014;19 (8):7–37. [Russian: Моисеев В.С., Мухин Н.А., Смирнов А.В., Кобалава Ж.Д., Бобкова И.Н., Виллевальде С.В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014;19(8):7-37]. DOI: 10.15829/1560-4071-2014-8-7-37</mixed-citation><mixed-citation xml:lang="en">Moiseev V. S., Mukhin N.A., Smirnov A.V., Kobalava Zh.D., Bobkova I.N., Villevalde S.V. et al. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology. 2014;19 (8):7–37. [Russian: Моисеев В.С., Мухин Н.А., Смирнов А.В., Кобалава Ж.Д., Бобкова И.Н., Виллевальде С.В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014;19(8):7-37]. DOI: 10.15829/1560-4071-2014-8-7-37</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">KGIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Nephrology and Dialysis. 2017;19(1):22–206. [Rusian: Клинические практические Рекомендации KDIGO 2012 по Диагностике и лечению хронической болезни почек. Нефрология и диализ. 2017;19(1):22-206]. DOI: 10.28996/1680-4422-2017-1-22-206</mixed-citation><mixed-citation xml:lang="en">KGIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Nephrology and Dialysis. 2017;19(1):22–206. [Rusian: Клинические практические Рекомендации KDIGO 2012 по Диагностике и лечению хронической болезни почек. Нефрология и диализ. 2017;19(1):22-206]. DOI: 10.28996/1680-4422-2017-1-22-206</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272</mixed-citation><mixed-citation xml:lang="en">Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N. M., Bazhan S.S. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations VI revision. Atherosclerosis and Dyslipidemias. 2017;3:5–22. [Russian: Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5-22]</mixed-citation><mixed-citation xml:lang="en">Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N. M., Bazhan S.S. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations VI revision. Atherosclerosis and Dyslipidemias. 2017;3:5–22. [Russian: Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5-22]</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tareeva I. E., Kutyrina I. M., Nikolaev A. Yu., Lifshits N. L., Shvetsov M. Yu. The braking of chronic renal failure. Terapeutic Archive. 2000;72 (6):9–14. [Russian: Тареева И. Е., Кутырина И. М., Николаев А. Ю., Лифшиц Н. Л., Швецов М. Ю. Пути торможения развития хронической почечной недостаточности. Терапевтический архив. 2000;72(6):9-14]</mixed-citation><mixed-citation xml:lang="en">Tareeva I. E., Kutyrina I. M., Nikolaev A. Yu., Lifshits N. L., Shvetsov M. Yu. The braking of chronic renal failure. Terapeutic Archive. 2000;72 (6):9–14. [Russian: Тареева И. Е., Кутырина И. М., Николаев А. Ю., Лифшиц Н. Л., Швецов М. Ю. Пути торможения развития хронической почечной недостаточности. Терапевтический архив. 2000;72(6):9-14]</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Muñoz SJ, ElGenaidi H. Cardiovascular risk factors afer liver transplantation. Liver Transplantation. 2005;11(S2):S52–6. DOI: 10.1002/lt.20602</mixed-citation><mixed-citation xml:lang="en">Muñoz SJ, ElGenaidi H. Cardiovascular risk factors afer liver transplantation. Liver Transplantation. 2005;11(S2):S52–6. DOI: 10.1002/lt.20602</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63(3):331–8. PMID: 9039919</mixed-citation><mixed-citation xml:lang="en">Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63(3):331–8. PMID: 9039919</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Imagawa DK, Dawson S, Holt CD, Kirk PS, Kaldas FM, Shackleton CR et al. Hyperlipidemia afer liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation. 1996;62(7):934–42. PMID: 8878387</mixed-citation><mixed-citation xml:lang="en">Imagawa DK, Dawson S, Holt CD, Kirk PS, Kaldas FM, Shackleton CR et al. Hyperlipidemia afer liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation. 1996;62(7):934–42. PMID: 8878387</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Munoz SJ, Deems RO, Moritz MJ, Martin P, Jarrell BE, Maddrey WC. Hyperlipidemia and obesity afer orthotopic liver transplantation. Transplantation Proceedings. 1991;23(1 Pt 2):1480–3. PMID: 1989271</mixed-citation><mixed-citation xml:lang="en">Munoz SJ, Deems RO, Moritz MJ, Martin P, Jarrell BE, Maddrey WC. Hyperlipidemia and obesity afer orthotopic liver transplantation. Transplantation Proceedings. 1991;23(1 Pt 2):1480–3. PMID: 1989271</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplantation. 2013;19(1):3–26. DOI: 10.1002/lt.23566</mixed-citation><mixed-citation xml:lang="en">Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplantation. 2013;19(1):3–26. DOI: 10.1002/lt.23566</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich S. Yu., Ivanova L. P., Lerman O. V., Lukina Yu. V., Zakharova A. V., Kiseleva N. V. The outpatient registry profle utilization for obesity patients surveying with the aim of food related and exercise related cardiovascular risk assessement. Cardiovascular Terapy and Prevention. 2017;16 (4):56–61. [Russian: Марцевич С. Ю., Иванова Л. П., Лерман О. В., Лукина Ю. В., Захарова А. В., Киселева Н. В. Использование амбулаторного регистра профиль с целью анкетирования пациентов с ожирением для оценки факторов сердечнососудистого риска, связанных с питанием и физической активностью. Кардиоваскулярная терапия и профилактика. 2017;16(4):56-61]. DOI: 10.15829/1728-8800-2017-4-56-61</mixed-citation><mixed-citation xml:lang="en">Martsevich S. Yu., Ivanova L. P., Lerman O. V., Lukina Yu. V., Zakharova A. V., Kiseleva N. V. The outpatient registry profle utilization for obesity patients surveying with the aim of food related and exercise related cardiovascular risk assessement. Cardiovascular Terapy and Prevention. 2017;16 (4):56–61. [Russian: Марцевич С. Ю., Иванова Л. П., Лерман О. В., Лукина Ю. В., Захарова А. В., Киселева Н. В. Использование амбулаторного регистра профиль с целью анкетирования пациентов с ожирением для оценки факторов сердечнососудистого риска, связанных с питанием и физической активностью. Кардиоваскулярная терапия и профилактика. 2017;16(4):56-61]. DOI: 10.15829/1728-8800-2017-4-56-61</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">All-Russian public organization of transplantologists “Russian transplantological society.” Methodical recommendation. Liver transplantation. [Russian: Общероссийская общественная организация трансплантологов «Российское трансплантологическое общество». Методические рекомендации. Трансплантация печени. 2016. Доступно на: htp://democenter.nitrosbase.com/clinrecalg5/Files/recomend/MP32.PDF]</mixed-citation><mixed-citation xml:lang="en">All-Russian public organization of transplantologists “Russian transplantological society.” Methodical recommendation. Liver transplantation. [Russian: Общероссийская общественная организация трансплантологов «Российское трансплантологическое общество». Методические рекомендации. Трансплантация печени. 2016. Доступно на: htp://democenter.nitrosbase.com/clinrecalg5/Files/recomend/MP32.PDF]</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ojo AO, Held PJ, Port FK, Wolfe R, Leichtman AB, Young EW et al. Chronic Renal Failure afer Transplantation of a Nonrenal Organ. New England Journal of Medicine. 2003;349(10):931–40. DOI: 10.1056/NEJMoa021744</mixed-citation><mixed-citation xml:lang="en">Ojo AO, Held PJ, Port FK, Wolfe R, Leichtman AB, Young EW et al. Chronic Renal Failure afer Transplantation of a Nonrenal Organ. New England Journal of Medicine. 2003;349(10):931–40. DOI: 10.1056/NEJMoa021744</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology. 2016;64(2):433–85. DOI: 10.1016/j.jhep.2015.10.006</mixed-citation><mixed-citation xml:lang="en">EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology. 2016;64(2):433–85. DOI: 10.1016/j.jhep.2015.10.006</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Vorobyeva M. A., Villevalde S.V., Kobalava Zh.D. Appointment of lipid-modulating therapy in hospitalized patients with ischemic stroke in real clinical practice. Eurasian Heart Journal. 2016;3:106. [Russian: Воробьева М.А., Виллевальде С.В., Кобалава Ж.Д. Назначение липидмодулирующей терапии госпитализированным пациентам с ишемическим инсультом в реальной клинической практике. Евразийский кардиологический журнал. 2016;3:106]</mixed-citation><mixed-citation xml:lang="en">Vorobyeva M. A., Villevalde S.V., Kobalava Zh.D. Appointment of lipid-modulating therapy in hospitalized patients with ischemic stroke in real clinical practice. Eurasian Heart Journal. 2016;3:106. [Russian: Воробьева М.А., Виллевальде С.В., Кобалава Ж.Д. Назначение липидмодулирующей терапии госпитализированным пациентам с ишемическим инсультом в реальной клинической практике. Евразийский кардиологический журнал. 2016;3:106]</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Akhmedzhanov N. M., Nebieridze D. V., Safaryan A. S., Vygodin V. A., Shuraev A. Yu., Tkacheva O. N. et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): part I. Rational Pharmacotherapy in Cardiology. 2015;11 (3):253–60. [Russian: Ахмеджанов Н. М., Небиеридзе Д. В., Сафарян А. С., Выгодин В. А., Шураев А. Ю., Ткачева О. Н. и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I. Рациональная фармакотерапия в кардиологии. 2015;11(3):253-60]</mixed-citation><mixed-citation xml:lang="en">Akhmedzhanov N. M., Nebieridze D. V., Safaryan A. S., Vygodin V. A., Shuraev A. Yu., Tkacheva O. N. et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): part I. Rational Pharmacotherapy in Cardiology. 2015;11 (3):253–60. [Russian: Ахмеджанов Н. М., Небиеридзе Д. В., Сафарян А. С., Выгодин В. А., Шураев А. Ю., Ткачева О. Н. и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I. Рациональная фармакотерапия в кардиологии. 2015;11(3):253-60]</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kulakov V.V., Villevalde S.V., Kobalava Zh.D. Prevalence of renal functional disorders in patients with arterial hypertension in real clinical practice. Eurasian Cardiology Journal. 2016;3:150–1. [Russian: Кулаков В.В., Виллевальде С.В., Кобалава Ж.Д. Распространенность нарушений функционального состояния почек у пациентов с артериальной гипертонией в реальной клинической практике. Евразийский кардиологический журнал. 2016;3:150-1]</mixed-citation><mixed-citation xml:lang="en">Kulakov V.V., Villevalde S.V., Kobalava Zh.D. Prevalence of renal functional disorders in patients with arterial hypertension in real clinical practice. Eurasian Cardiology Journal. 2016;3:150–1. [Russian: Кулаков В.В., Виллевальде С.В., Кобалава Ж.Д. Распространенность нарушений функционального состояния почек у пациентов с артериальной гипертонией в реальной клинической практике. Евразийский кардиологический журнал. 2016;3:150-1]</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Barysheva O. Yu., Kopyl V. E. Chronic kidney disease: prevalence, causes according to the register of the city polyclinic. CardioSomatics. 2017;8 (1):85–6. [Russian: Барышева О. Ю., Копыл В. Е. Хроническая болезнь почек: распространенность, причины по данным регистра городской поликлиники. CardioСоматика. 2017;8(1):85-6]</mixed-citation><mixed-citation xml:lang="en">Barysheva O. Yu., Kopyl V. E. Chronic kidney disease: prevalence, causes according to the register of the city polyclinic. CardioSomatics. 2017;8 (1):85–6. [Russian: Барышева О. Ю., Копыл В. Е. Хроническая болезнь почек: распространенность, причины по данным регистра городской поликлиники. CardioСоматика. 2017;8(1):85-6]</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Khurmi NS, Chang Y-H, Eric Steidley D, Singer AL, Hewit WR, Reddy KS et al. Hospitalizations for Cardiovascular Disease Afer Liver Transplantation in the United States: Liver Transplantation. Liver Transplantation. 2018;24 (10):1398–410. DOI: 10.1002/lt.25055</mixed-citation><mixed-citation xml:lang="en">Khurmi NS, Chang Y-H, Eric Steidley D, Singer AL, Hewit WR, Reddy KS et al. Hospitalizations for Cardiovascular Disease Afer Liver Transplantation in the United States: Liver Transplantation. Liver Transplantation. 2018;24 (10):1398–410. DOI: 10.1002/lt.25055</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Naesens M, Kuypers DRJ, Sarwal M. Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of the American Society of Nephrology. 2009;4(2):481–508. DOI: 10.2215/CJN.04800908</mixed-citation><mixed-citation xml:lang="en">Naesens M, Kuypers DRJ, Sarwal M. Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of the American Society of Nephrology. 2009;4(2):481–508. DOI: 10.2215/CJN.04800908</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">State register of medicinal products. Tacrolimus. Registration certifcate. [Russian: Государственный реестр лекарственных средств. Такролимус. Регистрационное удостоверение. Доступно на: htps://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=581dec0f-92f6-4a32-956c-8afcef5545e5&amp;t]</mixed-citation><mixed-citation xml:lang="en">State register of medicinal products. Tacrolimus. Registration certifcate. [Russian: Государственный реестр лекарственных средств. Такролимус. Регистрационное удостоверение. Доступно на: htps://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=581dec0f-92f6-4a32-956c-8afcef5545e5&amp;t]</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Got’e S. V., Moysyuk Ya. G. Transplantology. Pharmacotherapy without mistakes. – M.: E-noto; 431 p. [Russian: Готье С. В., Мойсюк Я. Г. Трансплантология. Фармакотерапия без ошибок. – М.: E-noto, 2014. – 431с]. ISBN 978-5-906033-05-6</mixed-citation><mixed-citation xml:lang="en">Got’e S. V., Moysyuk Ya. G. Transplantology. Pharmacotherapy without mistakes. – M.: E-noto; 431 p. [Russian: Готье С. В., Мойсюк Я. Г. Трансплантология. Фармакотерапия без ошибок. – М.: E-noto, 2014. – 431с]. ISBN 978-5-906033-05-6</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ribeiro H de S, Anastácio LR, Ferreira LG, Lagares EB, Lima AS, Correia MITD. Prevalence and factors associated with dyslipidemia afer liver transplantation. Revista Da Associacao Medica Brasileira (1992). 2014;60(4):365–72. PMID: 25211421</mixed-citation><mixed-citation xml:lang="en">Ribeiro H de S, Anastácio LR, Ferreira LG, Lagares EB, Lima AS, Correia MITD. Prevalence and factors associated with dyslipidemia afer liver transplantation. Revista Da Associacao Medica Brasileira (1992). 2014;60(4):365–72. PMID: 25211421</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gisbert C, Prieto M, Berenguer M, Bretó M, Carrasco D, de Juan M et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transplantation and Surgery: Ofcial Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 1997;3(4):416–22. PMID: 9346772</mixed-citation><mixed-citation xml:lang="en">Gisbert C, Prieto M, Berenguer M, Bretó M, Carrasco D, de Juan M et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transplantation and Surgery: Ofcial Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 1997;3(4):416–22. PMID: 9346772</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dehghani SM, Taghavi SAR, Eshraghian A, Gholami S, Imanieh MH, Bordbar MR et al. Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors. Journal of Gastroenterology. 2007;42(9):769–74. DOI: 10.1007/s00535-007-2092-2</mixed-citation><mixed-citation xml:lang="en">Dehghani SM, Taghavi SAR, Eshraghian A, Gholami S, Imanieh MH, Bordbar MR et al. Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors. Journal of Gastroenterology. 2007;42(9):769–74. DOI: 10.1007/s00535-007-2092-2</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Torchovskaya T. I., Kudinov V. A., Zakharova T. S., Markin S. S. Dysfunctional High-Density Lipoproteins: Role in Atherogenesis and Potential Targets for Phospholipid Terapy. Kardiologiia. 2018;58 (3):73–83. [Russian: Торховская Т. И., Кудинов В. А., Захарова Т. С., Маркин С. С. Дисфункциональные липопротеины высокой плотности: роль в атерогенезе и потенциальные мишени для фосфолипидной терапии. Кардиология. 2018;58(3):73-83]. DOI: 10.18087/cardio.2018.3.10101</mixed-citation><mixed-citation xml:lang="en">Torchovskaya T. I., Kudinov V. A., Zakharova T. S., Markin S. S. Dysfunctional High-Density Lipoproteins: Role in Atherogenesis and Potential Targets for Phospholipid Terapy. Kardiologiia. 2018;58 (3):73–83. [Russian: Торховская Т. И., Кудинов В. А., Захарова Т. С., Маркин С. С. Дисфункциональные липопротеины высокой плотности: роль в атерогенезе и потенциальные мишени для фосфолипидной терапии. Кардиология. 2018;58(3):73-83]. DOI: 10.18087/cardio.2018.3.10101</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Romayne Kurukulasuriya L, Athappan G, Saab G, Whaley Connell A, Sowers JR. Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Terapeutic Advances in Cardiovascular Disease. 2007;1(1):49–59. DOI: 10.1177/1753944707082714</mixed-citation><mixed-citation xml:lang="en">Romayne Kurukulasuriya L, Athappan G, Saab G, Whaley Connell A, Sowers JR. Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Terapeutic Advances in Cardiovascular Disease. 2007;1(1):49–59. DOI: 10.1177/1753944707082714</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Trevisan R, Dodesini AR, Lepore G. Lipids and Renal Disease. Journal of the American Society of Nephrology. 2006;17(4 suppl 2):S145–7. DOI: 10.1681/ASN.2005121320</mixed-citation><mixed-citation xml:lang="en">Trevisan R, Dodesini AR, Lepore G. Lipids and Renal Disease. Journal of the American Society of Nephrology. 2006;17(4 suppl 2):S145–7. DOI: 10.1681/ASN.2005121320</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Guckelberger O, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B et al. Cardiovascular risk factors in long-term follow-up afer orthotopic liver transplantation. Clinical Transplantation. 1997;11(1):60–5. PMID: 9067697</mixed-citation><mixed-citation xml:lang="en">Guckelberger O, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B et al. Cardiovascular risk factors in long-term follow-up afer orthotopic liver transplantation. Clinical Transplantation. 1997;11(1):60–5. PMID: 9067697</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Laryea M, Wat KD, Molinari M, Walsh MJ, McAlister VC, Marota PJ et al. Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events. Liver Transplantation. 2007;13(8):1109–14. DOI: 10.1002/lt.21126</mixed-citation><mixed-citation xml:lang="en">Laryea M, Wat KD, Molinari M, Walsh MJ, McAlister VC, Marota PJ et al. Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events. Liver Transplantation. 2007;13(8):1109–14. DOI: 10.1002/lt.21126</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sergienko I.V., Ansheles A.A., Kukharchuk V.V. Atherosclerosis and dyslipidemias: modern aspects of pathogenesis, diagnostics and treatment. – М.: ООО “Patis”; 140 p. [Russian: Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Атеросклероз и дислипидемии: современные аспекты патогенеза, диагностики и лечения. – М.: ООО «ПатиСС», 2017. – 140с]. ISBN 978-5-903630-88-2</mixed-citation><mixed-citation xml:lang="en">Sergienko I.V., Ansheles A.A., Kukharchuk V.V. Atherosclerosis and dyslipidemias: modern aspects of pathogenesis, diagnostics and treatment. – М.: ООО “Patis”; 140 p. [Russian: Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Атеросклероз и дислипидемии: современные аспекты патогенеза, диагностики и лечения. – М.: ООО «ПатиСС», 2017. – 140с]. ISBN 978-5-903630-88-2</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Mak RHK, De Fronzo R. Glucose and Insulin Metabolism in Uremia. Nephron. 1992;61(4):377–82. DOI: 10.1159/000186953</mixed-citation><mixed-citation xml:lang="en">Mak RHK, De Fronzo R. Glucose and Insulin Metabolism in Uremia. Nephron. 1992;61(4):377–82. DOI: 10.1159/000186953</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. American Journal of Physiology-Renal Physiology. 2006;290(2):F262–72. DOI: 10.1152/ajprenal.00099.2005</mixed-citation><mixed-citation xml:lang="en">Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. American Journal of Physiology-Renal Physiology. 2006;290(2):F262–72. DOI: 10.1152/ajprenal.00099.2005</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kaysen GA. Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney International. 2006;70:S55–8. DOI: 10.1038/sj.ki.5001979</mixed-citation><mixed-citation xml:lang="en">Kaysen GA. Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney International. 2006;70:S55–8. DOI: 10.1038/sj.ki.5001979</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF et al. End-stage renal disease (ESRD) afer orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72(12):1934–9. PMID: 11773892</mixed-citation><mixed-citation xml:lang="en">Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF et al. End-stage renal disease (ESRD) afer orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72(12):1934–9. PMID: 11773892</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Gröne EF, Gröne H-J. Does hyperlipidemia injure the kidney? Nature Clinical Practice Nephrology. 2008;4(8):424–5. DOI: 10.1038/ncpneph0863</mixed-citation><mixed-citation xml:lang="en">Gröne EF, Gröne H-J. Does hyperlipidemia injure the kidney? Nature Clinical Practice Nephrology. 2008;4(8):424–5. DOI: 10.1038/ncpneph0863</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. American Journal of Kidney Diseases: The Ofcial Journal of the National Kidney Foundation. 2000;35(4 Suppl 1):S117-131. PMID: 10766010</mixed-citation><mixed-citation xml:lang="en">Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. American Journal of Kidney Diseases: The Ofcial Journal of the National Kidney Foundation. 2000;35(4 Suppl 1):S117-131. PMID: 10766010</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Keane WF. Lipids and the kidney. Kidney International. 1994;46(3):910–20. PMID: 7996813</mixed-citation><mixed-citation xml:lang="en">Keane WF. Lipids and the kidney. Kidney International. 1994;46(3):910–20. PMID: 7996813</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Urazlina S.E., Zhdanova T.V., Nazarov A.V., Istomina A.S. Dyslipidemia in patients with chronic kidney disease. Ural medical journal. 2011;2 (80):124–7. [Russian: Уразлина С.Е., Жданова Т.В., Назаров А.В., Истомина А.С. Нарушения липидного обмена у больных с хронической почечной недостаточностью. Уральский медицинский журнал. 2011;2(80):124-7]</mixed-citation><mixed-citation xml:lang="en">Urazlina S.E., Zhdanova T.V., Nazarov A.V., Istomina A.S. Dyslipidemia in patients with chronic kidney disease. Ural medical journal. 2011;2 (80):124–7. [Russian: Уразлина С.Е., Жданова Т.В., Назаров А.В., Истомина А.С. Нарушения липидного обмена у больных с хронической почечной недостаточностью. Уральский медицинский журнал. 2011;2(80):124-7]</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Keane WF, O’Donnell MP, Kasiske BL, Kim Y. Oxidative modifcation of low-density lipoproteins by mesangial cells. Journal of the American Society of Nephrology: JASN. 1993;4(2):187–94. PMID: 8400082</mixed-citation><mixed-citation xml:lang="en">Keane WF, O’Donnell MP, Kasiske BL, Kim Y. Oxidative modifcation of low-density lipoproteins by mesangial cells. Journal of the American Society of Nephrology: JASN. 1993;4(2):187–94. PMID: 8400082</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Gröne HJ, Walli A, Gröne E, Niedmann P, Tiery J, Seidel D et al. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat. Laboratory Investigation; a Journal of Technical Methods and Pathology. 1989;60(3):433–46. PMID: 2927082</mixed-citation><mixed-citation xml:lang="en">Gröne HJ, Walli A, Gröne E, Niedmann P, Tiery J, Seidel D et al. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat. Laboratory Investigation; a Journal of Technical Methods and Pathology. 1989;60(3):433–46. PMID: 2927082</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality afer orthotopic liver transplantation. Transplantation. 2002;73(6):901–6. PMID: 11923689</mixed-citation><mixed-citation xml:lang="en">Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality afer orthotopic liver transplantation. Transplantation. 2002;73(6):901–6. PMID: 11923689</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
